Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer

Ye, Feng; Dewanjee, Saikat; Li, Yuehua; Jha, Niraj Kumar; Chen, Zhe-Sheng; Kumar, Ankush; Vishakha; Behl, Tapan; Jha, Saurabh Kumar; Tang, Hailin

doi:10.1186/s12943-023-01805-y

Molecular Cancer

Table 2 List of some selected ongoing trials with different immune checkpoint blockers in different subtypes of breast cancer

From: Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer

S. no	Phases	Breast cancer subtypes	Immuno-therapeutic agents	Estimated participants	Co-treatment	Recruitment status	Identifiers
Anti-PD-1/PD-L1 therapy
1	I	Advanced TNBC	Pembrolizumab	57	ZEN003694, nab-paclitaxel	Recruiting	NCT05422794
2	I	HLA-A2 + metastatic TNBC	Pembrolizumab	20	PVX-410 vaccine	Active, not recruiting	NCT03362060
3	I	TNBC	Pembrolizumab	Not clearly mentioned	CPI-006	Active, not recruiting	NCT03454451
4	I	Early-Stage TNBC	Pembrolizumab	12	Lenvatinib	Recruiting	NCT04427293
5	I	Metastatic TNBC	Pembrolizumab	11	TTAC-0001	Active, not recruiting	NCT03720431
6	I	TNBC	Pembrolizumab	15	Intraoperative radiation	Recruiting	NCT02977468
7	I (early)	Metastatic TNBC	Pembrolizumab	20	Bortezomib plus cisplatin injections; bortezomib followed by pembro/cis	Recruiting	NCT04265872
8	I	Advanced BC	Pembrolizumab	150	LY3475070	Recruiting	NCT04148937
9	I/II	Locally recurrent or metastatic TNBC	Pembrolizumab	211	Ladiratuzumab vedotin	Recruiting	NCT03310957
10	II	HER-2 − metastatic TNBC	Pembrolizumab	70	Nab-paclitaxel	Active, not recruiting	NCT02752685
11	II	TNBC	Pembrolizumab	26	Paclitaxel, cyclophosphamide, epirubicin	Recruiting	NCT05681728
12	II	TNBC or HR + /HER2 − BC	Pembrolizumab	23	Olaparib	Recruiting	NCT05203445
13	II	HR + localized inflammatory BC	Pembrolizumab	37	Hormonal therapy, radiation	Active, not recruiting	NCT02971748
14	II	HER2 − inflammatory BC	Pembrolizumab	81	EC-paclitaxel	Recruiting	NCT03515798
15	II	HER2 − BC and TNBC	Pembrolizumab	47	Decitabine followed by chemotherapy with cyclophosphamide, paclitaxel, carboplatin	Active, not recruiting	NCT02957968
16	II	TNBC or HR + /HER2 − BC	Pembrolizumab	56	Olaparib, Radiation	Recruiting	NCT04683679
17	II	Anthracycline- refractory TNBC	Pembrolizumab	30	Docetaxel, IL-12 gene therapy	Recruiting	NCT04095689
18	II	Early-stage TNBC	Pembrolizumab	29	AE37 Peptide vaccine	Recruiting	NCT04427293
19	II	TNBC	Pembrolizumab	460	Olaparib, carboplatin, gemcitabine	Active, not recruiting	NCT04191135
20	II	Metastatic TNBC	Pembrolizumab	40	Cyclophosphamide	Active, not recruiting	NCT02768701
21	II	Metastatic TNBC	Pembrolizumab	30	Nac-paclitaxel, carboplatin	Active, not recruiting	NCT03121352
22	II	Inoperable locally recurrent or metastatic TNBC	Pembrolizumab	65	Tavokinogene telseplasmid, immunopulse, nab-paclitaxel	Recruiting	NCT03567720
23	II	TNBC, PD-L1 −	Pembrolizumab	110	Sacituzumab govitecan	Recruiting	NCT04468061
24	II	Metastatic TNBC	Pembrolizumab	87	Carboplatin, Gemcitabine	Recruiting	NCT02755272
25	II	TNBC, BC	Pembrolizumab	12	IRX 2	Active, not recruiting	NCT04373031
26	II	TNBC, ER − , PR − , HER2 − , invasive BC	Pembrolizumab	51	Sacituzumab govitecan	Active, not recruiting	NCT04230109
27	II	TNBC, HR + , HER2 − , LN + BC	Pembrolizumab	120	Radiation Therapy Boost, Paclitaxel, Carboplatin, Cyclophosphamide, Doxorubicin, Capecitabine	Recruiting	NCT04443348
28	III	Inoperable locally recurrent or metastatic TNBC	Pembrolizumab	882	Nab-Paclitaxel, Paclitaxel, Gemcitabine, Carboplatin	Active, not recruiting	NCT02819518
29	I/II	Metastatic TNBC	Nivolumab	51	Romidepsin, cisplatin	Active, not recruiting	NCT02393794
30	I/II	Localized TNBC	Nivolumab	50	Paclitaxel, carboplatin, cabiralizumab	Active, not recruiting	NCT04331067
31	I/II	HER2 +	Nivolumab	390	BDC-1001	Recruiting	NCT04278144
32	II	TNBC	Nivolumab	45	Capecitabine	Active, not recruiting	NCT03487666
33	II	HR − , HER2 − , early stage/resectable BC	Nivolumab	80	Ipilimumab, core biopsy/cryoablation, breast surgery	Recruiting	NCT03546686
34	II	Metastatic TNBC	Nivolumab	52	Cisplatin, doxorubicin (low-dose)	Recruiting	NCT04159818
35	II	TNBC	Nivolumab	84	Radiation, doxorubicin (low-dose), cyclophosphamide, cisplatin	Active, not recruiting	NCT02499367
36	II	Metastatic TNBC	Nivolumab	78	Carboplatin	Active, not recruiting	NCT03414684
37	II	First-line metastatic TNBC	Nivolumab	114	Ipilimumab, capecitabine	Active, not recruiting	NCT03818685
38	II	HR + , HER2 − or TNBC	Cemiplimab	36	Paclitaxel, carboplatin (not mandatory), doxorubicin, cyclophosphamide	Recruiting	NCT04243616
39	II	Different BC subtypes	Cemiplimab	5000	AMG 386 with/without trastuzumab, AMG 479 plus metformin, AMG 386 plus trastuzumab, MK-2206 with/without trastuzumab, T-DM1 and pertuzumab, pertuzumab and trastuzumab, ganetespib ABT-888, neratinib, PLX3397, pembrolizumab (4 cycle), talazoparib plus irinotecan, patritumab and trastuzumab, pembrolizumab (8 cycle), SGN-LIV1A, durvalumab plus olaparib, SD-101 plus Pembrolizumab, tucatinib plus trastuzumab and pertuzumab, cemiplimab, cemiplimab plus REGN3767, trilaciclib with/without trastuzumab plus pertuzumab, SYD985, paclitaxel + dostarlimab encequidar + carboplatin with/ without trastuzumab, paclitaxel + encequidar + dostarlimab with/without trastuzumab, amcenestrant, amcenestrant plus abemaciclib, amcenestrant plus letrozole, ARX788, ARX788 plus cemiplimab, VV1 plus cemiplimab, datopotamab deruxtecan, datopotamab deruxtecan plus durvalumab, zanidatamab, lasofoxifene, Z-endoxifen	Recruiting	NCT01042379
40	I	Different BC subtypes	Avelumab	45	Palbociclib	Recruiting	NCT04360941
41	I/II	TNBC	Avelumab	197	Cyclophosphamide plus JX-594 dose escalation, cyclophosphamide plus JX-594, cyclophosphamide, avelumab plus JX-594 and cyclophosphamide	Recruiting	NCT02630368
42	II	TNBC	Avelumab	150	PF-04518600, utomilumab, binimetinib, sacituzumab govitecan, doxorubicin,	Recruiting	NCT03971409
43	II	BC, metastatic TNBC	Atezolizumab	75	Doxorubicin plus cyclophosphamide, placebo for atezolizumab	Active, not recruiting	NCT03164993
44	II	BC, metastatic TNBC	Atezolizumab	23	Talazoparib, radiation	Active, not recruiting	NCT04690855
45	II	TNBC	Atezolizumab	458	Carboplatin, paclitaxel, epirubicin, cyclophosphamide, surgery	Active, not recruiting	NCT04770272
46	II	TNBC and IV, HER2 − and invasive BC	Atezolizumab	106	Carboplatin	Active, not recruiting	NCT03206203
47	II	TNBC, invasive BC, breast adenocarcinoma	Atezolizumab	37	Nab-Paclitaxel	Active, not recruiting	NCT02530489
48	II	Advanced or metastatic TNBC	Atezolizumab	100	Paclitaxel, bevacizumab		NCT04408118
49	II	TNBC	Atezolizumab	284	Capecitabine or capecitabine (monotherapy)	Recruiting	NCT03756298
50	II	TNBC and Brain Metastasis	Atezolizumab	45	Stereotactic radiosurgery	Active, not recruiting	NCT03483012
51	II	Advanced TNBC	Atezolizumab	52	Stereotactic radiosurgery	Active, not recruiting	NCT03464942
52	III	Inoperable locally advanced or metastatic TNBC	Atezolizumab	180	Nab-paclitaxel	Active, not recruiting	NCT04148911
53	III	TNBC	Atezolizumab	1550	Atezolizumab, paclitaxel (neoadjuvant chemotherapy) carboplatin, doxorubicin, cyclophosphamide, epirubicin, (adjuvant continuation), surgery	Active, not recruiting	NCT03281954
54	III	TNBC	Atezolizumab	2300	Paclitaxel, doxorubicin/epirubicin, cyclophosphamide	Active, not recruiting	NCT03498716
55	III	Recurrent, inoperable locally advanced or metastatic TNBC	Atezolizumab	572	Gemcitabine, capecitabine, carboplatin	Recruiting	NCT03371017
56	III	TNBC	Atezolizumab	278	Carboplatin, nab-paclitaxel, anthracycline chemotherapeutic drug, cyclophosphamide or fluorouracil, epirubicin and cyclophosphamide	Active, not recruiting	NCT02620280
57	I	TNBC	Durvalumab	18	Neoantigen DNA vaccine	Active, not recruiting	NCT03199040
58	I	Stage 2/3 TNBC	Durvalumab	22	PVX-410, Hiltonol	Active, not recruiting	NCT02826434
59	I/II	TNBC	Durvalumab	171	Paclitaxel, carboplatin, oleclumab	Active, not recruiting	NCT02489448
60	I/II	Locally advanced luminal B HER2 −	Durvalumab	57	Paclitaxel, epirubicin, cyclophosphamide	Active, not recruiting	NCT03356860
61	I/II	TNBC	Durvalumab	200	Capivasertib, oleclumab paclitaxel, trastuzumab deruxtecan, datopotamab deruxtecan	Active, not recruiting	NCT03742102
62	II	Advanced and metastatic TNBC	Durvalumab	28	CFI-400945	Active, not recruiting	NCT04176848
63	II	Stage 4 BC AJCC v8, TNBC	Durvalumab	28	Olaparib	Recruiting	NCT03801369
64	II	Stage 4 BC AJCC v8, invasive TNBC	Durvalumab	70	Carboplatin, gemcitabine hydrochloride, nab-paclitaxel, peptide vaccine, poly ICLC, tremelimumab	Recruiting	NCT03606967
65	II	Breast neoplasm	Durvalumab	81	AZD6738, olaparib	Recruiting	NCT03740893
66	II	Different BC subtypes	Durvalumab	5000	Olaparib	Recruiting	NCT01042379
Anti-CTLA-4 therapy
67	II	Stage 4 BC AJCC v8, invasive BC, metastatic TNBC	Tremelimumab	70	Carboplatin, gemcitabine hydrochloride, nab-paclitaxel, peptide vaccine, poly ICLC, durvalumab	Recruiting	NCT03606967
68	I	Different types of cancers including ER − , PR − , HER2 − BC	Ipilimumab	234	XmAb®23,104	Recruiting	NCT03752398
69	I/II	Advanced solid tumors including BC	Ipilimumab	100	Pembrolizumab plus durvalumab	Recruiting	NCT05187338
70	I/II	Advanced solid tumors including metastatic BC	Ipilimumab	914	ONC-392	Recruiting	NCT04140526
71	II	HR − , HER2 − , early stage/resectable BC	Ipilimumab	80	Nivolumab, core biopsy/cryoablation, breast surgery	Recruiting	NCT03546686
72	II	HER2 − metastatic or inoperable BC	Ipilimumab	138	Nivolumab, bicalutamide	Recruiting	NCT03650894
73	I	Advanced solid tumors including TNBC	SI-B003 (a CTLA-4/PD-1 bispecific antibody)	159	-	Recruiting	NCT04606472
74	I/II	Inoperable locally advanced or metastatic cancers including BC	JK08 (CTLA-4 targeting IL-15 antibody fusion protein)	149	-	Recruiting	NCT05620134

BC Breast cancer, CTLA-4 cytotoxic T-lymphocyte-associated antigen-4, HER2 human epidermal growth factor receptor 2, HR Hormone receptor, PD-1 Programmed death receptor 1, PD-L1 Programmed death-ligand 1, PR progesterone receptor, TNBC Triple-negative breast cancer

Back to article page

ISSN: 1476-4598

Contact us

General enquiries: journalsubmissions@springernature.com